As of 2025-11-13, the EV/EBITDA ratio of E-Therapeutics PLC (ETX.L) is -2.56. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ETX.L's latest enterprise value is 24.99 mil GBP. ETX.L's TTM EBITDA according to its financial statements is -9.77 mil GBP. Dividing these 2 quantities gives us the above ETX.L EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 15.6x - 17.5x | 16.6x |
| Forward P/E multiples | 18.6x - 23.4x | 21.0x |
| Fair Price | (24.00) - (22.28) | (24.27) |
| Upside | -366.6% - -347.6% | -369.7% |
| Date | EV/EBITDA |